Does Mounjaro Carry a Blindness Risk? What the Evidence Shows

What is NAION, and has it been linked to GLP-1 medicines?

NAION (non-arteritic anterior ischaemic optic neuropathy) is a sudden reduction in blood supply to the optic nerve that can cause permanent, partial vision loss in the affected eye. It is rare, typically painless, and usually noticed as a shadow or blurred area in one eye on waking. It was on ophthalmologists' radar long before GLP-1 medicines existed, associated with cardiovascular risk factors including hypertension, sleep apnoea, and diabetes.

A 2024 study published in JAMA Ophthalmology reported a higher observed rate of NAION among people taking semaglutide compared with those taking non-GLP-1 medicines, particularly in patients who already had diabetic eye disease. Because tirzepatide shares the GLP-1 mechanism (though it also activates GIP receptors) researchers and regulators began examining whether the association might extend to Mounjaro. As of mid-2026, the MHRA and international regulators are reviewing the signal, but have not concluded that GLP-1 medicines cause NAION. An observed association in observational data is not the same as a proven cause.

For context, many patients in these studies had pre-existing conditions (particularly poorly controlled diabetes and hypertension) that independently raise NAION risk. Disentangling the medicine's contribution from the underlying disease burden is methodologically difficult, which is why the research is ongoing rather than resolved. You can read the broader risk profile for Mounjaro to see how this fits alongside other considerations.

What about diabetic retinopathy, is that a separate concern?

It is, and it deserves its own answer. Diabetic retinopathy is damage to blood vessels at the back of the eye caused by prolonged high blood sugar. When blood sugar drops quickly (as it can in the early weeks of any effective diabetes treatment, including tirzepatide) those already-fragile vessels can be stressed, temporarily worsening retinopathy. This phenomenon is not unique to GLP-1 medicines; it has been documented with insulin and other glucose-lowering therapies for decades.

The Mounjaro SmPC (the official prescribing document, available on the Electronic Medicines Compendium) lists worsening diabetic retinopathy as a known adverse reaction. Patients with existing diabetic eye disease should have that condition assessed and documented before starting treatment, and should tell their prescriber and eye specialist they are beginning tirzepatide. This is not a reason to avoid the medicine for everyone, it is a reason for proper clinical screening.

For people without diabetes, the retinopathy risk does not apply in the same way. The broader Mounjaro side-effects profile covers the full range of what is known across both diabetic and non-diabetic patients.

When should a vision change prompt urgent medical help?

The threshold for seeking help is low and deliberately so. Contact 111 or go to an eye casualty department (not a GP's routine appointment) if you notice any of the following while taking Mounjaro: sudden blurring, a new dark patch or shadow in your field of vision, painless vision loss in one eye (especially on waking), or any sudden change that comes on within hours. Do not self-monitor and wait. NAION, if it is the cause, progresses quickly and early assessment matters.

Other vision symptoms that warrant a same-day call to your prescriber rather than A&E: gradual blurring that develops over days, floaters that are new but mild, or any change you would describe as unusual but not sudden. If in doubt, err on the side of getting seen. The NHS patient page on tirzepatide lists urgent and non-urgent symptoms side by side, which is worth bookmarking.

You can report any suspected side effect (including vision changes) to the MHRA through the Yellow Card scheme. Patient reports are a genuine part of how post-market safety evidence accumulates; they are not just a formality. If you have questions about your individual situation or risk factors, our support team can connect you with a prescriber seven days a week.

How does a prescriber weigh this risk when assessing someone for Mounjaro?

A prescriber considering tirzepatide for someone with a history of eye disease (or with conditions that raise eye-disease risk, such as poorly controlled hypertension or long-standing type 2 diabetes) will factor that into the clinical picture. It may mean recommending an ophthalmology check before starting, adjusting titration pace to minimise rapid glucose shifts, or in some cases concluding that a different approach is more appropriate. Some patients also ask whether symptoms such as tiredness on Mounjaro are connected to the same underlying factors, and that is worth raising with your prescriber too.

This is exactly why these medicines are prescription-only: the decision requires a clinician who knows your medical history, not a checklist. At nume, every consultation is read and assessed by a GPhC-registered Independent Prescriber, and the same clinical review happens before every repeat order. If you have pre-existing eye conditions, declare them in full, the prescriber cannot weigh a risk they are not told about. There is also a broader discussion of Mounjaro and cancer risk for patients who want to understand the full landscape of safety signals under review, and our overview of Mounjaro risk brings together the key safety considerations in one place. Patients who want to understand specific symptoms before their consultation, including whether Mounjaro causes tiredness, will find detailed answers there. The free consultation is the right place to start that conversation.